WAT
55
2
R
71
4
LLY
37
-3
VMC
57
4
EXC
53
-3
XYL
49
4
CA
38
6
HON
67
2
DHI
48
4
PFG
45
3
ES
34
3
ADSK
70
2
SLB
55
2
NWS
66
-3
EQIX
64
2
HCA
44
-2
MTB
67
2
MA
64
7
NSC
60
3
PM
62
-2
WAT
55
2
R
71
4
LLY
37
-3
VMC
57
4
EXC
53
-3
XYL
49
4
CA
38
6
HON
67
2
DHI
48
4
PFG
45
3
ES
34
3
ADSK
70
2
SLB
55
2
NWS
66
-3
EQIX
64
2
HCA
44
-2
MTB
67
2
MA
64
7
NSC
60
3
PM
62
-2
Financhill
Back

Lumos Pharma 10K Form

Sell
30

LUMO
Lumos Pharma

Last Price:
4.31
Seasonality Move:
7.61%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive LUMO News And Ratings

See the #1 stock for the next 7 days that we like better than LUMO

LUMO Financial Statistics

Sales & Book Value

Annual Sales: $2.05M
Cash Flow: $-5.01M
Price / Cash Flow: 0
Annual Sales: $0.57
Price / Book: 7.59

Profitability

EPS (TTM): -4.29000
Net Income (TTM): $-34.92M
Gross Margin: $934K
Return on Equity: -182.95%
Return on Assets: -112.43%

Lumos Pharma Earnings Forecast

Key Lumos Pharma Financial Ratios

  • The Gross Profit Margin over the past 2 years for LUMO is 100.00%.
  • The Selling, General & Administrative Expenses for LUMO have been equal to 807.85% of Gross Profit Margin.
  • The Research & Development expenses have been 1,077.33% of Revenue.
  • The Interest Expense is -0.52% of Operating Income.
  • Per Share Earnings over the last 16 years have been positive in 6 years.

Lumos Pharma Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: LUMO
CUSIP: 55028X
Website: lumos-pharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 2.66
Quick Ratio: 2.11

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

LUMO Technical Analysis vs Fundamental Analysis

Sell
30
Lumos Pharma (LUMO) is a Sell

Is Lumos Pharma a Buy or a Sell?

  • Lumos Pharma stock is rated a Sell
    The current Lumos Pharma [LUMO] share price is $4.31. The Score for LUMO is 30, which is 40% below its historic median score of 50, and infers higher risk than normal.